BeiGene Initiated at Market Outperform by JMP Securities
JMP Securities Initiates Coverage On BeiGene With Market Outperform Rating, Announces Price Target of $288
BeiGene Analyst Ratings
JMP Securities Initiates BeiGene(BGNE.US) With Buy Rating, Announces Target Price $288
BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Maintains Target Price $198
Hold Rating on BeiGene Amid Mixed Sales Performance and Competitive Pressures
Morgan Stanley Maintains BeiGene(BGNE.US) With Buy Rating, Cuts Target Price to $307
Morgan Stanley Maintains BeiGene(BGNE.US) With Buy Rating, Cuts Target Price to $307
BeiGene Analyst Ratings
J.P. Morgan Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $200
TD Cowen Initiates BeiGene(BGNE.US) With Buy Rating, Announces Target Price $254
TD Cowen Sticks to Its Buy Rating for BeiGene (BGNE)
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $284
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $284
Jefferies Sticks to Their Buy Rating for BeiGene (BGNE)
BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $198
Hold Rating on BeiGene Amid Mixed Drug Performance and Strong Pipeline Potential
BeiGene's Strong Financial and Clinical Prospects Solidify Buy Rating
BeiGene Analyst Ratings
BeiGene's Brukinsa Drives Strong Growth and Justifies Buy Rating